Presentations support Calquence efficacy and tolerability with long-term follow-up in mantle cell lymphoma and pooled safety data in chronic lymphocytic leukaemia

Emerging pipeline shows promise with novel targets and mechanisms to treat resistant and aggressive blood cancers

AstraZeneca will present new research aimed at addressing key unmet needs facing patients with blood cancers at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, held virtually from 5 to 8 December 2020.

The Company will present 27 abstracts spanning five medicines and potential new medicines and eight different haematology conditions that demonstrate the Company’s commitment to advancing haematology research and treatments for patients living with haematologic malignancies.

Key data presentations include:

A pooled analysis of data from four trials - ELEVATE TN, ASCEND, ACE-CL-001 and 15-H-0016 - expanding on the cardiovascular safety profile of Calquence monotherapy treatment for patients with chronic lymphocytic leukaemia (CLL)
Extended follow-up data from the pivotal Phase II ACE-LY-004 trial that support long-term treatment with Calquence in adult patients with relapsed or refractory mantle cell lymphoma (MCL)
Data on Calquence in combination with venetoclax and either obinutuzumab or rituximab in patients with CLL, showing a safety profile consistent with previous trials with high complete responses and undetectable minimal residual disease rates after a median follow-up of 26.9 months, with minimal to no drug-drug interactions in the Phase Ib ACE-CL-003 trial
First-in-human data from the potential new medicine B-cell maturation antigen (BCMA)-targeted antibody drug conjugate, MEDI2228, presenting data on safety and efficacy at all dose levels in relapsed or refractory multiple myeloma
Data showing pre-clinical evidence of overcoming resistance in relapsed or refractory MCL from the dual BCL2/XL inhibitor, AZD4320, which blocks the anti-apoptotic effect of BCL2 and BCLXL
Phase I data from the anti-inducible co-stimulator anti-ICOS monoclonal antibody, MEDI-570, demonstrating promising early clinical activity in poor-risk refractory and heavily pre-treated patients with angioimmunoblastic T-cell lymphoma
Multiple studies on roxadustat, the first in a new class of medicines evaluating its clinical effectiveness and safety profile in both the dialysis dependent and non-dialysis dependent anaemia of CKD patient populations
Data on roxadustat assessing efficacy in anaemia secondary to lower-risk myelodysplastic syndrome (MDS) regardless of baseline factors. In approximately one in three patients MDS leads to acute myeloid leukaemia.1
Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: “Our data at ASH this year continue to support Calquence as a well-tolerated treatment with impressive efficacy and safety across multiple blood cancers, reinforcing physicians’ confidence in treating patients with Calquence over the long term. Data at the meeting will also explore Calquence combinations with commonly used therapies, showing potential across a variety of regimens in chronic lymphocytic leukaemia to best suit the unique needs of each patient.”

José Baselga, Executive Vice President, Oncology R&D, said: “As we rapidly expand our presence in haematology, we are focused on identifying novel targets and mechanisms of action that can address the most urgent unmet needs across various haematological malignancies. Our early portfolio at this year’s ASH clearly demonstrates our commitment to following the science in combating treatment-resistant and rare blood cancers.”

Key AstraZeneca presentations during the 62nd ASH Annual Meeting and Exposition
see & read more on
https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-demonstrates-strengths-in-haematology-with-robust-data-at-ash-2020.html